Advaxis, Inc. (OTCMKTS:ADXS) Sees Significant Decline in Short Interest
Advaxis, Inc. (OTCMKTS:ADXS) Sees Significant Decline in Short Interest
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) was the target of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 2,400 shares, a decrease of 7.7% from the October 31st total of 2,600 shares. Based on an average daily trading volume, of 4,100 shares, the short-interest ratio is currently 0.6 days.
Advaxis, Inc.(OTCMKTS: ADXS——获取评级)是11月空头利息大幅减少的目标。截至11月15日,空头利息总额为2400股,较10月31日的2600股下降了7.7%。根据4,100股的平均每日交易量,目前的空头利率为0.6天。
Advaxis Price Performance
Advax 价格表现
ADXS stock opened at $1.66 on Monday. Advaxis has a 12 month low of $1.02 and a 12 month high of $30.56. The firm has a 50 day simple moving average of $1.89 and a 200 day simple moving average of $2.49. The firm has a market cap of $3.01 million, a PE ratio of -16.55 and a beta of 2.07.
周一,ADXS股票开盘价为1.66美元。Advaxis的12个月低点为1.02美元,为12个月高点30.56美元。该公司的50天简单移动平均线为1.89美元,200天简单移动平均线为2.49美元。该公司的市值为301万美元,市盈率为-16.55,beta值为2.07。
Advaxis (OTCMKTS:ADXS – Get Rating) last posted its earnings results on Monday, September 12th. The biotechnology company reported ($3.83) earnings per share for the quarter.
Advaxis(OTCMKTS: ADXS — 获取评级)最后一次公布财报是在9月12日星期一。这家生物技术公司报告了本季度每股收益(3.83美元)。
Analyst Ratings Changes
分析师评级变化
Advaxis Company Profile
Advaxis 公司简介
(Get Rating)
(获取评级)
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis, Inc是一家处于临床阶段的生物技术公司,专注于在美国发现、开发和商业化专有的单核细胞增生李斯特菌 (Lm) 技术抗原递送产品。该公司正在开发用于治疗转移性前列腺癌的ADXS-PSA;正在开发用于治疗转移性前列腺癌的第 2 期临床试验的 ADXS-503;以及用于治疗前列腺癌的 ADXS-504。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- Intel is a Sleeping Giant Ready to Awaken
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- 免费获取 StockNews.com 关于 Advaxis (ADXS) 的研究报告的副本
- 英特尔是准备觉醒的沉睡巨人
- 为什么 CSL Ltd 的股票值得一看
- MarketBeat:本周回顾 11/28 — 12/02
- Okta Inc庆祝盈利突破但他们能否维持增长?
- 机构正在收购安巴雷拉,你应该吗?
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Advaxis 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Advaxis及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。